• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Appoints Carl Aure as Chief Financial Officer

    10/25/21 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    SALT LAKE CITY, Oct. 25, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer. Mr. Aure brings more than 24 years of finance and accounting experience including over 15 years in the direct selling industry. He will join the Company on October 25, 2021.

    "We are pleased to welcome Carl to the LifeVantage team. His deep financial expertise along with an extensive background in direct selling and international operations make him the ideal candidate to lead all aspects of finance, accounting, tax and treasury," said Steve Fife, President and Chief Executive Officer of LifeVantage. "Carl is also a proven leader with a strategic mindset and significant M&A experience, factors that will be instrumental in executing our plan to accelerate growth over the next several years."

    Mr. Aure most recently served as Chief Accounting Officer for New Age, Inc., a social selling company with over 1,100 employees and operations in more than 50 international markets. He joined New Age, Inc. in 2018 as Senior Vice President, Corporate Controller, following the acquisition of Morinda Holdings, Inc. ("Morinda"). From 2005 to 2018, Mr. Aure worked at Morinda in progressive levels of responsibility across finance and accounting roles. Prior to Morinda, Mr. Aure spent eight years at KPMG, LLP, most recently as a Senior Manager. Mr. Aure is a Certified Public Accountant and holds a Master of Professional Accountancy from the University of Utah.   

    "LifeVantage is a dynamic company with a unique, high-quality product and significant base of loyal distributors and customers. I am excited to be joining this exceptional team to build on its accomplishments and further execute against the Company's strategic goals," said Mr. Aure.

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company's line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, and Daily Wellness dietary supplements, TrueScience® is the Company's line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]

     



    Primary Logo

    Get the next $LFVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      6/17/25 4:11:27 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Aure Carl converted options into 2,401 shares and sold $36,769 worth of shares (2,746 units at $13.39), decreasing direct ownership by 0.26% to 133,303 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:31 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Fife Steven R covered exercise/tax liability with 21,064 shares, decreasing direct ownership by 3% to 611,307 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:22 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Neufeld Alissa converted options into 2,667 shares and covered exercise/tax liability with 2,799 shares, decreasing direct ownership by 0.14% to 91,569 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:12 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    SEC Filings

    See more
    • Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:06:34 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:05:28 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      2/5/25 4:05:56 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

      SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

      1/16/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

      SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

      8/26/24 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

      SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e

      7/22/24 6:27:51 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Financials

    Live finance-specific insights

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025

      SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after th

      4/22/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      7/31/24 8:07:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:29:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:27:16 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Convention 2025 Empowers Consultants to 'Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth

      SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed

      4/28/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care